[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 56, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 48, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9262, "open": 0.9167, "dayLow": 0.9167, "dayHigh": 0.9399, "regularMarketPreviousClose": 0.9262, "regularMarketOpen": 0.9167, "regularMarketDayLow": 0.9167, "regularMarketDayHigh": 0.9399, "beta": 0.56, "forwardPE": -0.6725581, "volume": 9507, "regularMarketVolume": 9507, "averageVolume": 108283, "averageVolume10days": 38040, "averageDailyVolume10Day": 38040, "bid": 0.6524, "ask": 1.2, "bidSize": 200, "askSize": 200, "marketCap": 24718148, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 6.47, "priceToSalesTrailing12Months": 3.3653026, "fiftyDayAverage": 1.095, "twoHundredDayAverage": 1.766185, "currency": "USD", "enterpriseValue": -47875884, "floatShares": 12093178, "sharesOutstanding": 26298700, "sharesShort": 30296, "sharesShortPriorMonth": 45484, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0011999999, "heldPercentInsiders": 0.36023, "heldPercentInstitutions": 0.35479, "shortRatio": 0.39, "shortPercentOfFloat": 0.0019, "impliedSharesOutstanding": 26298700, "bookValue": 1.255, "priceToBook": 0.7489243, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -27642000, "trailingEps": -1.01, "forwardEps": -1.94, "enterpriseToRevenue": -6.518, "enterpriseToEbitda": 1.742, "52WeekChange": -0.54313725, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LVTX", "underlyingSymbol": "LVTX", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "firstTradeDateEpochUtc": 1616765400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f272303e-4305-36b0-b7df-26c82acd7c44", "messageBoardId": "finmb_546792242", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.9399, "targetHighPrice": 3.002729, "targetLowPrice": 2.0014694, "targetMeanPrice": 2.341866, "targetMedianPrice": 2.0214107, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 78884000, "totalCashPerShare": 3.0, "ebitda": -27476000, "totalDebt": 6290000, "quickRatio": 5.257, "currentRatio": 5.364, "totalRevenue": 7345000, "debtToEquity": 19.065, "revenuePerShare": 0.271, "returnOnAssets": -0.18031, "returnOnEquity": -0.63118, "grossProfits": 7191000, "freeCashflow": -18466376, "operatingCashflow": -28604000, "grossMargins": 0.97903, "operatingMargins": -3.81743, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]